Recce Pharmaceuticals Doses Patients For UTI/Urosepsis Clinical Study

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has dosed 4 subjects with its interventional treatment in a Phase I/II study of people with urinary tract infection/Urosepsis.

The cohort was treated with 3,000mg of R327 over a 20-minute time frame.

RECCE® 327 is an intravenous and topical therapy developed to treat serious and potentially life-threatening infections.

These can often present as Gram-positive and Gram-negative bacteria including their superbug forms.

The data received from this cohort will support a Phase II UTI/Urosepsis efficacy clinical study.

About Urosepsis

Urosepsis is sepsis caused by urinary tract infections, including cystitis, or lower urinary tract and bladder infections.

They can also present as pyelonephritis, or upper urinary tract and kidney infections.

The company has been looking to develop a new class of synthetic anti-infectives where there are antibiotic-resistant superbugs.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives.

The RECCE 435 drug is as an orally administered therapy for bacterial infections, and RECCE® 529 for viral infections.


Recce received $11.17 million in non-dilutive cash from Endpoints Capital, reflecting R&D rebate credits for FY23/24.

It also received an Advanced Overseas finding awarded by the Australian Government of $54.9 million, the largest awarded in Australian history.

The finding underscored the advance funds from Endpoints Capital, an R&D financing firm.

The share price of Recce is $0.42, down from $0.96 two years ago.

The advanced funding provided by Endpoints Capital could accelerate Recce’s multiple clinical programs.


Articles of Interest